September 2023

The S&P/ASX 200 is trading 1.37 per cent lower at 7,064.90. Futures The SPI futures are down 103 points. Best and worst performers The best-performing sector is REITs, down 0.35 per cent. The worst-performing sector is Financials, down 1.95 per cent. The best-performing large cap is South32 (ASX:S32), trading 1.65 per cent higher at $3.385.

Alex Parks – CEO and Managing Director – Prominence Energy (ASX:PRM) is an ASX listed oil and gas exploration and development company.

Brendan Stats – CEO – TMK Energy Limited (ASX:TMK) is a gas exploration company listed on the Australian Stock Exchange. TMK holds a 67% interest in the Gurvantes XXXV Project located in the South Gobi Basin of Mongolia and also holds a 20% interest in the Talisman Depp Project containing the Napoleon Structure located in

Tor McCaul – Managing Director – Comet Ridge Limited (ASX: COI) is a publicly listed Australian energy company focused on the development of natural ga

Ken Aitken – Managing Director – Metgasco (ASX:MEL) is a petroleum (oil and gas) exploration and production company, listed on the Australian Securities Exchange.

Thomas Nador – CEO – Buru Energy (ASX:BRU) is an oil and gas producer and explorer with its core area of activity in the in the northwest Western Australia in the onshore Canning Basin. The Company is also actively participating in the new energy economy with interests in natural hydrogen, CCS and battery minerals.

Phil McNamara – Director – Emperor Energy (ASX:EMP) is a diversified energy company with upstream and downstream assets in Australia. The company’s strategic asset Vic/P47 in the Gippsland Basin next to the BHP/ExxonMobil Kipper field. 

Managing Director of Pacgold Limited (ASX:PGO) Tony Schreck discusses the company’s key asset the Alice River Gold Project. Abbey Phillipps: We’re talking today with Pacgold, ASX Code PGO. The company has a market cap of around $19 million. Pacgold is a gold exploration company focused on progressing its key asset; The Alice River Gold Project

Immutep (ASX:IMM; NASDAQ:IMMP) announces the regulatory authorisation of “efti”, which is the Company’s proprietary soluble LAG-3 protein, for the use in clinical trials across multiple European countries. In response, Marc Voigt, CEO of Immutep, said, “Commercial scale manufacturing of efti for use in clinical trials is a significant achievement and brings us closer to realising